GT Biopharma Inc reports results for the quarter ended in December - Earnings Summary

GT Biopharma

30/03/2023 23:49

* GT Biopharma Inc  GTBP.OQ  reported a quarterly adjusted
loss
of 18 cents​​ per share for the quarter ended in December. The
mean expectation of two analysts for the quarter was for a loss
of 17 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GT Biopharma Inc's reported EPS for the quarter was a loss
of 18
cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * GT Biopharma Inc shares had fallen by 45.8% this quarter.
    * The company reported a quarterly loss of $5.58 million.
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $3.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 10:49 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.17          -0.18          Missed
 Sep. 30 2022      -0.11          -0.22          Missed
 Jun. 30 2022      -0.17          -0.10          Beat
 Mar. 31 2022      -0.31          -0.17          Beat